Transgene to Showcase Preclinical Data on Mpox Vaccine at WCID
Event summary
- Transgene will present preclinical data on its TG-MVA vaccine candidates against mpox at the World Congress on Infectious Diseases (WCID) on June 25–27, 2026.
- TG-MVACL, produced using a scalable cell line-based manufacturing process, is the preferred candidate for further development.
- Preclinical results demonstrate protective effects in mice and non-human primates challenged with the monkeypox virus (MPXV).
- Transgene is evaluating options to advance the TG-MVA program while maintaining focus on its myvac® platform for cancer immunotherapies.
The big picture
Transgene’s expansion into prophylactic vaccines for infectious diseases marks a strategic pivot from its core focus on cancer immunotherapies. The company’s expertise in viral-vector engineering is being leveraged to address biosecurity needs, particularly in the wake of rising concerns over Orthopoxvirus-related diseases. The development of TG-MVA underscores the growing importance of scalable manufacturing solutions in vaccine development, a critical factor in ensuring supply resilience during pandemics.
What we're watching
- Development Strategy
- Whether Transgene can secure partnerships or funding to advance TG-MVA while maintaining focus on its core cancer immunotherapy platform.
- Regulatory Pathway
- The pace at which Transgene can transition from preclinical data to human trials for TG-MVACL.
- Market Positioning
- How TG-MVACL’s scalable manufacturing process will position it against existing mpox vaccines like MVA-BN®.
Related topics